Visit Contract Pharma at Booth 1205

Alcami Expands Analytical Capabilities

03.06.17

Invests in Bruker's D8 Discover HTS System for high-throughput X-Ray diffraction screening

Alcami has invested in the installation of a Bruker D8 Discover HTS high-throughput X-ray diffraction (XRD) analysis system at its site in Weert, The Netherlands. As part of a collaboration agreement, Alcami will use the D8 Discover HTS to add XRD capabilities to their laboratory service portfolio and make it available as part of their workflow-integrated solution.

The D8 Discover HTS combines advanced sample analysis throughput capabilities with great flexibility. This system perfectly matches the application requirements of the pharmaceutical industry for crystallization studies, polymorph screening, structure solution, phase identification and crystallite size determination under ambient and non-ambient conditions. With its high-throughput screening capability, the D8 Discover HTS provides opportunities for optimization of the development and production of pharmaceuticals.

"We are pleased to supply our latest high-throughput screening solution, the D8 Discover HTS, to Alcami," said Lutz Bruegemann, general manager XRD and vice president, Bruker AXS. "High-throughput screening of well plates using X-ray diffraction is a powerful and important analysis technique for accelerating the development and improving the quality of pharmaceutical products.”

Ted Dolan, chief operating officer, Alcami, said, “As we continue to further invest in our people, technology, equipment and capabilities across all sites, we are pleased to partner with Bruker in bringing this unique system to our Weert, Netherlands, facility The addition of the D8 Discover HTS to our center of excellence for solid-state chemistry in Weert will further enhance our capabilities and expertise in this area, including our ProForm Select integrated service offering for solid-state chemistry and formulation development to help the pharma/biotech industry meet important milestones and maintain stability in drug development."